Nuclera, the biotechnology company enabling rapid protein expression and purification screening through its eProtein Discovery benchtop protein platform, today announced its entry into the Tech Nation Future Fifty 2024 cohort, a unique program designed for the UK's next generation of unicorn founders. We announced that we were selected as participants. The most promising late-stage technology ventures. It was announced today at an official event hosted by the UK Department for Science, Innovation and Technology at 10 Downing Street. This is for 2024.1 It is made up of 25 companies and has raised a total of £1.3bn.
This year's Future Fifty cohort includes some of the best venture companies in biotechnology, quantum computing, and artificial intelligence. Nuclera joins bit.bio as the first biotech company in Future Fifty's history to join the program.
Recognized as one of the UK's most prestigious programmes, Future Fifty is supported by the Department for Science, Innovation and Technology and represents the largest network of pre-IPO companies in the country. As the only UK-wide accelerator program tailored for late-stage ventures, Future Fifty has backed some of the UK's most prominent unicorns, including Monzo, Deliveroo, Starling Bank and Revolut. The program is exclusive to the most promising Series B+ ventures and was recently redesigned to focus on the themes of access, growth, and well-being. We provide founders and senior leadership teams with the contacts, tools, and resources they need to remove barriers to growth and become the world's leading brands.
Dr. Michael Chen, CEO and co-founder of Nuclera, said: “Joining the Future Fifty program as part of the 2024 cohort is testament to the power of Nuclera’s growth and our vision for the eProtein Discovery System. Recognized as one of the UK’s most exciting growth stage companies This highlights what we have already accomplished and we look forward to continuing our current trajectory with the support of Tech Nation.”
Nuclera was recommended by Tech Nation's selection committee and ecosystem supporters for the company's ability to solve complex problems in creative ways, one of the program's key selection criteria. The custom protein reagents required for drug discovery are difficult to manufacture, both in terms of cost and time. Nuclera's eProtein Discovery platform overcomes this unmet need by providing rapid access to difficult proteins within 48 hours on benchtop systems. Accelerating the drug discovery process by up to 30x, this platform provides sequences and optimal conditions to inform protein manufacturing, including applications such as small molecule drug discovery, synthetic biology, and vaccine development.
For more information about Nuclera's eProtein Discovery platform, please visit https://www.nuclera.com/system/.
- Future Fifty “Meet the Cohort”: https://technation.io/meet-the-future-fifty-cohort-of-2024/
